Group items tagged

The National Heart, Lung, and Blood Institute invites cooperative agreement (U01) applications to serve as the Research Center (RC) for the Molecular Atlas of Lung Development Program (LungMAP), Phase 2. The overall objective of LungMAP is to better understand human lung development through building an open-access reference resource of a comprehensive, dynamic, 3-D molecular atlas of the late-stage developing human lung with data and reagents available to the research community. Phase 2 of LungMAP will continue to generate and integrate high-resolution, multiscale molecular profiles associated with spatial information to provide molecular characterizations of functionally and anatomically defined cell types in the developing human lung. Phase 2 of LungMAP will focus on human lung only and will extend the scope to cover normal lung development into early adulthood (up to 25 years old), as well as abnormal lung development in selected neonatal and pediatric rare lung diseases. The purpose of the LungMAP RCs will be to generate the molecular profiling data of the developing human lung. Applicants are not required to have been funded in Phase 1 (RFA-HL-14-008) in order to submit applications for Phase 2.

Age is the number one risk factor for diagnosis of many age-related lung diseases, including COPD and pulmonary fibrosis. Despite this, little is known regarding the interactions that likely occur between the molecular and cellular mechanisms of disease and the changes in molecules and cells that can be attributed to normal aging. In fact, very little is known about the normal aging process in the lung at the cellular and molecular level. In 2015, the National Heart, Lung, and Blood Institute (NHLBI) and the National Institute on Aging (NIA) co-sponsored a workshop that identified a major knowledge gap in the understanding of normal lung aging in humans, as well as the need to develop a map of molecular changes that occur during normal aging in the lung that can serve as a reference for studies of age-related lung diseases.

The Lung Cancer Research Foundation's pilot grant program provides funding for innovative research focused on the prevention, diagnosis, treatment, and cure of lung cancer. Grants of up to $150,000 over two years will be awarded in support of projects in one or more of the following areas of lung cancer research: lung cancer biology; prevention and screening for early detection; identification of new biomarkers and the development of targeted therapies; development of more effective and less toxic therapies; supportive measures for people with lung cancer and their families; and quality of care and outcomes research.

Through the program, grants of $50,000 per year for up to two years will be awarded to junior investigators on the path to independence for research on the mechanisms and biology of interstitial lung disease.The Dalsemer Research Grant is for $50,000 per year, for up to two years. Grants are subjected to annual review and may be granted for two years. The second year of support is based on demonstrating satisfactory progress, as well as, the availability of funding from the Lung Association. Applicants should be on-track to pursue a career in lung heath research with a mentor who has a demonstrated history of lung disease research and mentorship.

The International Union Against Tuberculosis and Lung Disease is accepting applications for the 2018 Karel Styblo Public Health Prize. The annual prize honors the contributions of a health worker or a community organization  to tuberculosis control over a period of ten years or more. The award consists of a full fellowship to attend the Union World Conference on Lung Health (including full delegate badge, travel, accommodation, and per diem), a cash award of $2,000, and a certificate (presented at the conference). Honorees may request that the fellowship portion of the award be used for a delegate who would not otherwise be able to attend the conference.

The purpose of this Funding Opportunity Announcement (FOA) is to support new and innovative epidemiology research in heart, lung, blood, and/or sleep diseases, disorders, and/or phenotypes. Through this FOA, the National Heart, Lung, and Blood Institute (NHLBI) aims to establish a new epidemiology cohort of at least 2000 participants to stimulate research on a wide range of heart, lung, blood, and/or sleep research hypotheses.

The Journalist to Journalist Project of the National Press Foundation is working with the International Union Against Tuberculosis and Lung Disease to offer all-expenses-paid fellowships for health journalists to cover the 44th Union World Conference on Lung Health in Paris, France. Fellowship winners will attend three days of expert training from Tuesday to Thursday, 29-31 October, then cover the conference through Sunday, 3 November 2013.

The National Heart, Lung, and Blood Institute invites applications for a Research Coordinating Center (RCC) to support projects from RFA-HL-20-003 Disparities Elimination through Coordinated Interventions to Prevent and Control Heart and Lung Disease Risk (DECIPHeR), to test late-stage (T4) implementation strategies for optimally and sustainably delivering proven-effective, evidence-based, multi-level interventions to reduce or eliminate cardiovascular and/or pulmonary health disparities and promote and improve population health in high-burden communities. The DECIPHeR RCC will coordinate activities across all of the DECIPHeR projects, including coordinating and managing in-person and virtual network steering committee meetings and working groups; promoting collaboration and communication among investigators and the broader research community; coordinating network outreach activities; promoting skills development in implementation science; organizing, establishing, and managing a global implementation data safety and monitoring board (DSMB); and providing clinical study and site monitoring for DECIPHeR awards. For the purpose of this FOA, T4 implementation research is defined as research to identify strategies to achieve sustainable uptake of proven-effective interventions into routine clinical and public health practice and community-based settings and maximize the positive impact on population health.

LUNGevity's Career Development Awards for Translational Research program was created to support future research leaders who will keep the field of lung cancer research vibrant with new ideas. Applicants must be within the first five years of their faculty appointment. The Career Development Awards are mentored awards; a mentoring plan is part of the required submission. Projects that will be funded in 2018 are expected to have a direct impact on the early detection of lung cancer or on the outcomes of lung cancer, or to provide a clear conceptual or experimental foundation for the future development of methods for early detection and/or individualized treatment, including through targeted therapy and immunotherapy. Career Development Awards may be for a maximum of $300,000: $100,000 per year for 3 years

The Innovation Award is for $75,000 per year, for up to two years. The award is intended to support highly promising investigators with stellar track records of accomplishment, who have the potential to advance the field of lung disease science. Successful applicants are investigators with evidence of prior excellence and productivity in the early stages of their careers; applicants must have held a K or R type award within three years prior to applying for this Lung Association award.

The National Heart, Lung, and Blood Institute invites applications for a Research Coordinating Center (RCC) to support projects from RFA-HL-20-003 Disparities Elimination through Coordinated Interventions to Prevent and Control Heart and Lung Disease Risk (DECIPHeR), which will test late-stage (T4) implementation research strategies for optimally and sustainably delivering proven-effective, evidence-based multi-level interventions to reduce or eliminate cardiovascular and/or pulmonary health disparities, and that promote and improve population health in high-burden communities (see RFA-HL-20-003). The DECIPHeR RCC will coordinate activities across all of the DECIPHeR projects, including coordinating and managing in-person and virtual network steering committee meetings and working groups; promoting collaboration and communication among investigators and the broader research community; coordinating network outreach activities; promoting skills development in implementation science; and organizing, implementing, and managing a global implementation data safety and monitoring board (DSMB) and providing clinical study and site monitoring for DECIPHeR awards. For the purpose of this FOA, late-stage (T4) implementation research is defined as research to identify strategies to achieve sustainable uptake of proven-effective interventions into routine clinical and public health practice and community-based settings and maximize the positive impact on population health.

The Lung Cancer Research Foundation's grant program provides funding for innovative research focused on the prevention, diagnosis, treatment and cure of lung cancer. The Foundation encourages applications for projects investigating a wide variety of research topics.

The purpose of this Funding Opportunity Announcement (FOA) is to invite grant applications to establish new and innovative epidemiology cohort studies that will prospectively follow at least 2,000 participants and are designed to study a wide range of research hypotheses related to heart, lung, blood, and/or sleep phenotypes. Through this FOA, the National Heart, Lung, and Blood Institute (NHLBI) will support activities required to establish a new cohort, including identification and recruitment of cohort participants, detailed baseline data collection on all participants, biospecimen collection and storage, study infrastructure, and data quality control and analysis.

The FY18 LCRP Career Development Award supports early-career, independent investigators to conduct impactful research under the mentorship of an experienced lung cancer researcher as an opportunity to obtain the funding, mentoring, and experience necessary for productive, independent careers at the forefront of lung cancer research. This award is intended to support impactful research projects with an emphasis on discovery. Submissions from and partnerships with investigators at Department of Defense (DoD) military treatment facilities and laboratories, and Department of Veterans Affairs (VA) medical centers and research laboratories are strongly encouraged.

This Funding Opportunity Announcement (FOA) seeks grant applications for a Research Coordinating Center (RCC) to support associated "Heart, Lung, and Blood Co-morbiditieS Implementation Models in People Living with HIV (HLB SIMPLe)" UG3/UH3 phased cooperative agreements that propose to optimally and sustainably address late-stage implementation research questions to address the delivery of proven-effective prevention and treatment interventions for heart, lung, blood, and sleep (HLBS) comorbid diseases and disorders in people living with HIV (PLHIV) in World Bank designated low- and middle-income countries (LMICs) and Small Island Developing States (SIDS). For the purposes of this FOA, late-stage implementation research is defined as research to identify strategies to achieve sustainable uptake of proven-effective interventions in routine clinical, public health, and community-based settings and maximize the positive impact on population health. The RCC will coordinate the collaborative efforts of the global alliance of funded UG3/UH3 phased cooperative agreements conducting late-stage implementation research within the following geographical regions: East Asia and the Pacific, Europe and Central Asia, Latin America and the Caribbean, Middle East and North Africa, South Asia, and Sub-Saharan Africa. The HLB SIMPLe RCC will coordinate activities including in-person and virtual Network Steering Committee meetings, subcommittee meetings, and working groups; promote collaboration and communication among investigators and the broader research community; coordinate network outreach activities; coordinate joint research and capacity building efforts conducted across the HLB SIMPLe alliance; and organize, implement, and manage a global implementation research data safety and monitoring board (DSMB). Also listed under UG3/UH3

Career Development Award supports early-career, independent investigators to conduct impactful research under the mentorship of an experienced lung cancer researcher as an opportunity to obtain the funding, mentoring, and experience necessary for productive, independent careers at the forefront of lung cancer research. This award is intended to support impactful research projects with an emphasis on discovery. Submissions from and partnerships with investigators at military treatment facilities, military labs, and Department of Veterans Affairs (VA) medical centers and research laboratories are strongly encouraged.Preliminary data are not required. However, logical reasoning and a sound scientific rationale for the proposed research must be demonstrated.Key elements of this award are as follows.

The National Heart, Lung, and Blood Institute invites cooperative agreement (U01) applications to investigate and define cellular and molecular events, including host genetic factors, underlying the pathogenesis of HIV-associated lung diseases (e.g., COPD and pulmonary hypertension). Biospecimens and clinical data from HIV-infected patients and controls should be utilized. Clinical translation is encouraged to the extent that it is possible. Both independent (site-specific) and collaborative research with other groups funded by this FOA will be conducted under this program. The goals are to identify disease sub-phenotypes, potential biomarkers to predict risk, progression, and outcome, and molecular targets to help design therapeutic interventions.

This Funding Opportunity Announcement (FOA) seeks applications for the design and development of technologies to monitor health or deliver care in a real-time, accessible, effective, and minimally obtrusive way for older adults with a chronic heart, lung, blood, or sleep (HLBS) condition. These technologies may be novel sensor or monitoring systems, home-use point-of-care devices, home or mobile therapy or rehabilitation tools, or information systems and should have the goal of fostering healthy and independent living for aging adults with HLBS conditions. The development of such technologies should incorporate specific human factors for aging adults including disabilities, mild impairments, as well as chronic HLBS conditions. Technology usability for these populations must be incorporated early in the development of the design. Usability considerations include but are not limited to patient-facing displays, hearing and visual impairments, tactile limitations, literacy, and design preferences between men and women. These improvements in technology design could yield more accurate and earlier detection of changes that may interfere with healthy and independent living for older adults.

The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The overarching goal of this National Heart, Lung, and Blood Institute (NHLBI) R25 program is to support mentoring and research education activities that enhance the diversity of the biomedical, behavioral and clinical research workforce. The major goal of this R25 program is to establish long-term mentoring that will enable junior faculty who are underrepresented in the biomedical sciences as defined by NOT-OD-18-122, to develop a research program and obtain NIH funding. This FOA specifically invites applications from senior faculty, established researchers, and experienced mentors to develop and direct the Summer Institutes of the Programs to Increase Diversity Among Individuals Engaged in Health-Related Research (PRIDE) program in order to mentor promising eligible junior faculty who have specific scientific interests in heart, lung, blood and sleep (HLBS) disorders research. To accomplish the stated overarching goal, this FOA will support creative educational activities with a primary focus on Research Experiences and Mentoring Activities.

This Funding Opportunity Announcement (FOA) is to support studies that are essential, yet also sufficient, for investigators to make definitive decisions about the designs of important clinical trials within NHLBI's mission, the prevention and treatment of heart, lung, blood, and sleep disorders. This mechanism may be used to test the feasibility of novel and efficient (pragmatic) trial designs, as well as determine the feasibility of an intervention, intervention parameters, subject availability, or other information essential to complete the design of a trial. Applications should demonstrate that the proposed pilot studies are both necessary and sufficient to permit definitive decisions about the design of the subsequent clinical trial. Applicants who propose solely to write a protocol or manual of operations or to develop infrastructure for a clinical trial will not be considered appropriate for this announcement. The NHLBI anticipates that the R34 award period will yield robust investigator-initiated clinical trial grant applications for the evaluation of interventions for the treatment or prevention of heart, lung, blood, or sleep disorders.